Comparable historical financial information

Excludes P&F segment sales[1]

November 6, 2025

© Solventum 2025. All rights reserved.

[1] See non-GAAP financial measures for description of adjustments

Non-GAAP financial measures

Solventum is providing certain comparable historical financial information for the each of the quarters in the year ended December 31, 2024, and the first three quarters of 2025 to assist investors in comparing its future and past operating results. The comparable historical financial information provides investors historical information adjusted to exclude the impact of the Company's divestiture of the Purification & Filtration business with the exception of the remaining Drinking Water Filtration product category. By excluding the impact of the P&F divestiture in the attached supplemental information, the Company believes investors will more readily be able to compare the Company's future results to its past performance.

The unaudited comparable historical financial information adjusts historical net sales, gross margin, operating income, operating income margin, non-operating expense, income before income taxes, provision for income taxes, tax rate, net income, and diluted EPS to reflect the above-described modifications. Except for matters noted above affecting changes in presentation, no other information in the Company's previously filed reports is being updated for events or developments that occurred subsequent to the filing of such reports. This information should be read in conjunction with, and as a supplement to, information contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, including Management's Discussion and Analysis of Results of Operations and Financial Condition and the Company's condensed consolidated financial statements and notes thereto.

In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. These non-GAAP financial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance, and the Company uses these measures as an indication of the strength of the Company and its ability to generate cash. Refer to the reconciliations of financial measures such as organic sales growth, adjusted operating income and adjusted operating income margin, adjusted earnings per share, and free cash flow. Further information and reconciliation of these non-GAAP measures (and organic sales growth) to the most directly comparable GAAP measure can be found in Solventum's November 6, 2025, press release.

Solventum calculates forward-looking non-GAAP financial measures; including organic sales growth, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted diluted earnings per share, and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures.

The Q1, Q2, and Q3 2025 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum's website: investors.solventum.com.

© Solventum 2025. All rights reserved.

Comparable sales history Q1 FY24 to Q3 FY25

as adjusted for P&F divestiture

(Millions)	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	FY 2024	Q1 FY25	Q2 FY 25	Q3 FY 25
Advanced Wound Care	$441	$460	$468	$466	$1,835	$448	$467	$485
Infection Prevention & Surgical Solutions	678	702	713	708	2,802	710	750	722
MedSurg	1,119	1,162	1,182	1,174	4,637	1,157	1,218	1,206
Dental	335	331	313	315	1,295	328	338	340
HIS	317	328	326	336	1,306	329	339	345
All other[1]	66	87	81	72	306	76	77	77
Comparable net sales	**$1,838**	**$1,908**	**$1,902**	**$1,897**	**$7,544**	**$1,890**	**$1,972**	**$1,968**

Above unaudited sales for Q1 2024 to Q3 2025 have been adjusted to exclude P&F segment sales and include the retained Drinking Water Filtration business in 'All other'. No changes have been made for MedSurg, Dental or HIS segments. See historical 10-Q and 10-K filings for GAAP net sales per segment as previously reported.

[1] All other includes what had previously been called Corporate and Unallocated, plus the retained Drinking Water Filtration business.

© Solventum 2025. All rights reserved.

Comparable sales growth metrics Q3 FY25 and YTD FY25

as adjusted for P&F divestiture

(Millions, except percentages)	Q3 FY24	Q3 FY25	Reported Growth	Currency Impact	Constant Currency	Other	Organic Growth
Advanced Wound Care	$468	$485	3.5%	0.8%	2.7%	-%	2.7%
Infection Prevention & Surgical Solutions	713	722	1.2	1.1	0.1	-	-
MedSurg	1,182	1,206	2.1	1.0	1.1	-	1.1
Dental	313	340	8.4	1.9	6.5	-	6.5
HIS	326	345	5.9	0.3	5.6	-	5.6
All other[1]	81	77	(5.4)	0.4	(5.8)	-	(5.8)
Comparable net sales	**$1,902**	**$1,968**	**3.5%**	**1.0%**	**2.5%**	-%	**2.4%**

(Millions, except percentages)	YTD FY24	YTD FY25	Reported Growth	Currency Impact	Constant Currency	Other	Organic Growth
Advanced Wound Care	$1,369	$1,400	2.2%	0.2%	2.0%	(0.1)%	2.1%
Infection Prevention & Surgical Solutions	2,093	2,182	4.2	0.1	4.1	(0.5)	4.6
MedSurg	3,463	3,581	3.4	0.1	3.3	(0.3)	3.6
Dental	979	1,006	2.8	0.5	2.3	(0.3)	2.5
HIS	971	1,012	4.3	0.1	4.2	-	4.2
All other[1]	234	230	(2.0)	0.1	(2.1)	5.6	(7.6)
Comparable net sales	**$5,647**	**$5,830**	**3.2%**	**0.6%**	**2.7%**	**-%**	**3.0%**

[1] All other includes what had previously been called Corporate and Unallocated, plus the retained Drinking Water Filtration business.

Note: Above sales for Q3 2024, Q3 2025, Q3 YTD 2024, and Q3 YTD 2025 have been adjusted to exclude P&F segment sales and include the retained Drinking Water Filtration business in 'All other'. No changes have been made for MedSurg, Dental or HIS segments. See historical 10-Q and 10-K filings for GAAP net sales per segment as previously reported. Above schedule is unaudited.

© Solventum 2025. All rights reserved.

Comparable historical Non-GAAP P&L

($ Millions, except per share data)	Q3 FY25 Non GAAP[1]	P&F divestiture Adjustments[2]	Comparable Q3 FY25 Non-GAAP[3]	Q3 YTD FY25 Non GAAP[1]	P&F divestiture Adjustments[2]	Comparable Q3 YTD FY25 Non-GAAP[3]
Net sales	2,096	(128)	1,968	6,327	(497)	5,830
Gross margin	1,170	(57)	1,113	3,530	(225)	3,305
% of sales	*55.8%*	*0.7%*	*56.6%*	*55.8%*	*0.9%*	*56.7%*
Operating income	431	(22)	409	1,312	(80)	1,232
Operating income margin	*20.6%*	*0.2%*	*20.8%*	*20.7%*	*0.4%*	*21.1%*
Non-operating expense	94	(29)	65	320	(110)	210
Income before income taxes	337	7	343	992	30	1,022
Provision for income taxes	74	1	75	198	6	204
Tax Rate	21.8%	21.8%	21.8%	20.0%	20.4%	20.0%
Net income	263	5	269	794	24	817
Diluted EPS	$1.50	$0.03	$1.53	$4.53	$0.14	$4.67

To provide a view of Solventum's historical results to aid investors in comparing historical to continuing operations, Solventum has provided comparable Non-GAAP P&L metrics for Q3 FY25 and Q3 YTD FY25, excluding the newly divested P&F business.

[1] All numbers are Non-GAAP except for Net Sales and Non-Operating expense. See accompanying reconciliation.

[2] Adjustments reflect the removal of historical results of operations of the P&F segment excluding the retained Drinking Water Filtration business, for quarterly periods ending March 31, 2025, June 30, 2025, and September 30, 2025. Adjustments assume the benefit of debt paydown from sale proceeds at an average annual interest expense of ~5.5%. Adjustments also include costs that are reported in Corporate and Unallocated that are directly related to the P&F segment excluding Drinking Water Filtration. The adjustments have been tax-effected, where deemed appropriate.

[3] Excludes P&F segment sales with exception of the retained Drinking Water Filtration business.

NOTE: Above unaudited reconciliation does not reflect the combined $0.03 Q3 EPS or $0.06 YTD EPS added benefit for Asset Held for Sale, which is captured in the reported Non-GAAP results consistent with the accounting treatment for P&F assets following announcement of the divestiture through the completion of the sale.

© Solventum 2025. All rights reserved.

Historical non-GAAP P&L reconciliation

© Solventum 2025. All rights reserved.

Q3 FY25 non-GAAP reconciliation

($ Millions, except per share data)	Q3 FY25 GAAP	Amortization	Restructuring	3M Spin-off & Separation-related Costs	Certain Litigation-related Costs	Purification and Filtration Separation-related	Gain on Sale of Business	Loss on Debt Extinguishment, Net	Q3 FY25 non-GAAP
Net sales	2,096								2,096
Gross margin	1,135		(2)	37					1,170
% of sales	54.2%		(0.1%)	1.8%					55.8%
R&D	183	(36)	(0)	(3)					144
% of sales	8.7%	(1.7%)	(0.0%)	(0.1%)					6.9%
SG&A	780	(41)	(4)	(120)	(2)	(18)			595
% of sales	37.2%	(2.0%)	(0.2%)	(5.7%)	(0.1%)	(0.9%)			28.4%
Operating expense[1]	963	(77)	(4)	(123)	(2)	(18)			739
Gain on sale of business	(1,518)						1,518		-
Operating income	1,690	77	2	160	2	18	(1,518)		431
Operating income margin	80.6%	3.7%	0.1%	7.6%	0.1%	0.9%	(72.3%)		20.6%
Interest expense, net	89								89
Loss on debt extinguishment, net	82							(82)	-
Other non-op expense/(income), net	5								5
Income before income taxes	1,514	77	2	160	2	18	(1,518)	82	337
Provision for income taxes	248	12	1	37	-	3	(247)	20	74
Net income	1,266	65	1	123	2	15	(1,271)	62	263
Diluted EPS	$7.22	$0.37	-	$0.71	$0.01	$0.09	($7.25)	$0.35	$1.50

solventum

[1]Operating expense includes the combination of research and development and selling, general and administrative expense line items from the Consolidated Statements of Income

© Solventum 2025. All rights reserved.

Q3 YTD FY25 non-GAAP reconciliation

($ Millions, except per share data)	Q3 YTD FY25 GAAP	Amortization	Restructuring	3M Spin-off & Separation-related Costs	Certain Litigation-related Costs	Purification and Filtration Separation-related	Gain on Sale of Business	Loss on Debt Extinguishment, Net	Q3 YTD FY25 non-GAAP
Net sales	6,327								6,327
Gross margin	3,424		9	98					3,530
% of sales	54.1%		0.1%	1.5%					55.8%
R&D	564	(110)	(5)	(11)					439
% of sales	8.9%	(1.7%)	(0.1%)	(0.2%)					6.9%
SG&A	2,321	(126)	(14)	(323)	(29)	(49)			1,780
% of sales	36.7%	(2.0%)	(0.2%)	(5.1%)	(0.5%)	(0.8%)			28.1%
Operating expense[1]	2,885	(235)	(19)	(335)	(29)	(49)			2,218
Gain on sale of business	(1,518)						1,518		-
Operating income	2,057	235	28	433	29	49	(1,518)		1,312
Operating income margin	32.5%	3.7%	0.4%	6.8%	0.5%	0.8%	(24.0%)		20.7%
Interest expense, net	296								296
Loss on debt extinguishment, net	82							(82)	-
Other non-op expense/(income), net	24								24
Income before income taxes	1,655	235	28	433	29	49	(1,518)	82	992
Provision for income taxes	162	36	7	100	6	10	(143)	20	198
Net income	1,493	199	21	333	22	39	(1,374)	62	794
Diluted EPS	$8.53	$1.14	$0.12	$1.90	$0.13	$0.22	($7.85)	$0.35	$4.53

solventum

[1]Operating expense includes the combination of research and development and selling, general and administrative expense line items from the Consolidated Statements of Income

© Solventum 2025. All rights reserved.